PJP vs XLV

Key Takeaways

• Different structures, different scopes: PJP is a concentrated, pharmaceuticals-focused fund of roughly 28 holdings, while XLV is a broad, market-capitalization-weighted fund spanning the entire U.S. health care sector.
• Cost gap: XLV carries a net expense ratio of about 0.08%, versus roughly 0.58% for PJP, giving XLV a clear structural cost advantage over long holding periods.
• Diversification profile: XLV holds 60-plus names across pharmaceuticals, biotechnology, medical equipment, and providers; PJP concentrates almost entirely in drug manufacturers and biotech.
• Concentration risk: XLV's top holding, LLY, represents roughly 15% of assets, while PJP spreads weight more evenly across pharma leaders at roughly 5% to 6% each.
• Tickeron AI Verdict: Between the two, Tickeron's AI currently favors XLV for its lower cost, broader diversification, and deeper liquidity.

Introduction

Investors seeking health care exposure often reach for an exchange-traded fund (ETF) without realizing how different two "health care" products can be. The Invesco Pharmaceuticals ETF (PJP) and the Health Care Select Sector SPDR Fund (XLV) both sit in the health care complex but do not compete directly. PJP offers a narrowly focused, factor-driven bet on U.S. drugmakers, while XLV provides diversified access to the entire sector, from pharma to insurers to medical devices. Comparing them clarifies how sector exposure, cost, and concentration shape an investor's risk profile.

Invesco Pharmaceuticals ETF (PJP) Overview

PJP is a passively managed fund that seeks to track the Dynamic Pharmaceutical Intellidex Index. Rather than weighting by market value, the Intellidex methodology evaluates U.S. pharmaceutical companies using fundamental and risk criteria, including price momentum, earnings momentum, quality, management action, and valuation. The fund typically holds roughly 28 names and rebalances quarterly. Its top holdings are concentrated among large-cap drugmakers, including ABBV, PFE, GILD, LLY, AMGN, JNJ, MRK, and ABT. Sector allocation skews heavily toward pharmaceuticals (roughly two-thirds) and biotechnology (about 29%), with a small sliver of health care equipment. The fund charges a net expense ratio of about 0.58% and is classified as non-diversified.

Health Care Select Sector SPDR Fund (XLV) Overview

XLV is a passively managed fund that tracks the Health Care Select Sector Index, which comprises the health care constituents of the S&P 500. Using a replication strategy, the fund is market-capitalization-weighted and holds approximately 60 to 64 stocks spanning pharmaceuticals, health care equipment and supplies, providers and services, biotechnology, and life sciences tools. Its top holdings include LLY, JNJ, ABBV, MRK, UNH, TMO, AMGN, GILD, ABT, and PFE. With a net expense ratio of about 0.08% and tens of billions in assets under management (AUM), XLV is among the largest and most liquid health care ETFs available, though it remains non-diversified under securities law.

Industry and Thematic Backdrop

Both funds operate within a health care sector shaped by innovation cycles and regulatory scrutiny. Demand for GLP-1 (glucagon-like peptide-1) weight-loss and diabetes therapies has driven outsized gains for select drugmakers, particularly LLY. Meanwhile, pharmaceutical pricing reform, patent expirations, and merger-and-acquisition (M&A) activity continue to influence sentiment. Broader macro forces, including interest rate expectations and defensive rotation, also matter: health care is often treated as a lower-volatility, non-cyclical allocation. For PJP, these dynamics are concentrated in drug pricing and pipeline momentum. For XLV, the same catalysts are diluted across insurers, device makers, and life sciences suppliers, producing a steadier but less targeted exposure profile.

Performance and Positioning Comparison

In recent months and market cycles, relative performance has hinged on the strength of megacap pharmaceuticals. Because XLV carries a roughly 15% weight in LLY, it has benefited directly from the obesity-drug rally while retaining ballast from defensive holdings such as UNH. PJP, by contrast, spreads its exposure more evenly, muting single-stock swings but concentrating risk within a narrower industry slice. XLV's historical beta of roughly 0.6 and its diversification across sub-industries have generally translated into lower volatility, whereas PJP's pharma-heavy tilt can amplify sector-specific drawdowns from pricing headlines or regulatory news. From a cost perspective, XLV's materially lower expense ratio compounds into a long-term performance edge before any alpha from factor selection is considered.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of securities using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending names, breakout candidates, and emerging opportunities far more efficiently than manual screening. Explore the AI Screener to refine your own ETF comparison and sector exposure research.

Tickeron AI Verdict

On a structural basis, Tickeron's AI would currently favor XLV. The fund's roughly 0.08% expense ratio is materially lower than PJP's 0.58%, an advantage that compounds over time. Its broader diversification across more than 60 holdings and multiple health care sub-industries reduces single-stock and single-therapy concentration risk, while its deeper liquidity and lower historical volatility support more stable relative positioning. PJP remains a viable, more concentrated expression of pharmaceutical momentum, but its higher cost and narrower footprint introduce greater idiosyncratic risk. Accordingly, XLV appears better aligned with investors seeking efficient, diversified sector exposure.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations